Depressive Symptoms in Crohn's Disease: Relationship with Immune Activation and Tryptophan Availability
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Crohn's disease (CD) is associated with immune activation and depressive symptoms. This study determines the impact of anti-tumor necrosis factor (TNF)-α treatment in CD patients on depressive symptoms and the degree to which tryptophan (TRP) availability and immune markers mediate this effect. Fifteen patients with CD, eligible for anti-TNF-α treatment were recruited. Disease activity (Harvey-Bradshaw Index (HBI), Crohn's Disease Activity Index (CDAI)), fatigue (Multidimensional Fatigue Inventory (MFI)), quality of life (Inflammatory Bowel Disease Questionnaire (IBDQ)), symptoms of depression and anxiety (Symptom Checklist (SCL-90), Beck Depression Inventory (BDI), Hamilton Depression Rating Scale (HDRS)), immune activation (acute phase proteins (APP)), zinc and TRP availability were assessed before treatment and after 2, 4 and 8 weeks. Anti-TNF-α increased IBDQ scores and reduced all depression scores; however only SCL-90 depression scores remained decreased after correction for HBI. Positive APPs decreased, while negative APPs increased after treatment. After correction for HBI, both level and percentage of γ fraction were associated with SCL-90 depression scores over time. After correction for HBI, patients with current/past depressive disorder displayed higher levels of positive APPs and lower levels of negative APPs and zinc. TRP availability remained invariant over time and there was no association between SCL-90 depression scores and TRP availability. Inflammatory reactions in CD are more evident in patients with comorbid depression, regardless of disease activity. Anti-TNF-α treatment in CD reduces depressive symptoms, in part independently of disease activity; there was no evidence that this effect was mediated by immune-induced changes in TRP availability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
An improved Bonferroni procedure for multiple tests of significance
SIMES, R. J. (1986) · Biometrika · doi:10.1093/biomet/73.3.751 · Cited by 2,396
The SCL-90 and the MMPI: A Step in the Validation of a New Self-Report Scale
Derogatis, L. R., Rickels, K., & Rock, A. F. (1976) · British Journal of Psychiatry · doi:10.1192/bjp.128.3.280 · Cited by 2,298 · cited 1×
“In addition, symptoms of depression and anxiety were assessed by self-report using the Beck Depression Inventory (BDI) [35,36] and the Symptom Checklist (SCL-90) [37].”
MethodRaison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617
Leonard, B., & Maes, M. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.12.005 · Cited by 805
Maes, M., Leonard, B. E., Myint, A. M., Kubera, M., & Verkerk, R. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.12.017 · Cited by 700
Self-citationDepressive disorders and immunity: 20 years of progress and discovery
Irwin, M. R., & Miller, A. H. (2007) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2007.01.010 · Cited by 676
Raison, C. L., Dantzer, R., Kelley, K. W., Lawson, M. A., Woolwine, B. J., Vogt, G., Spivey, J. R., Saito, K., & Miller, A. H. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.116 · Cited by 630 · cited 1×
“It has been argued that IFN-c induced depression is associated with induction of IDO that increases levels of kynurenine (KYN), which in turn leads to formation of neurotoxic metabolites, 3-hydroxykynurenine and quinolinic acid, rather than just TRP degradation by itself [13,39,44,47,48,49].”
BackgroundMittermaier, C., Dejaco, C., Waldhoer, T., Oefferlbauer-Ernst, A., Miehsler, W., Beier, M., Tillinger, W., Gangl, A., & Moser, G. (2004) · Psychosomatic Medicine · doi:10.1097/01.psy.0000106907.24881.f2 · Cited by 532 · cited 2×
“There are numerous studies showing that depression exacerbates CD and predicts lower remission rates in CD [5,6,7,12].”
BackgroundResultInterferon-alpha–induced changes in tryptophan metabolism
Capuron, L., Neurauter, G., Musselman, D. L., Lawson, D. H., Nemeroff, C. B., Fuchs, D., & Miller, A. H. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00173-2 · Cited by 493
Capuron, L., Ravaud, A., Neveu, P. J., Miller, A. H., Maes, M., & Dantzer, R. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4000995 · Cited by 473 · cited 1×
“In contrast to earlier studies showing decreased TRP/CAA ratios in patients with depression [21,24,25,26,27] and correlations between depressive symptoms and TRP levels in IFN-c induced depression [45,46], we did not find any increase in TRP/CAA ratio over time and there was no association over time between SCL-90 dep…”
ResultWichers, M. C., Koek, G. H., Robaeys, G., Verkerk, R., Scharpé, S., & Maes, M. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001600 · Cited by 445 · cited 2×
“It has been argued that IFN-c induced depression is associated with induction of IDO that increases levels of kynurenine (KYN), which in turn leads to formation of neurotoxic metabolites, 3-hydroxykynurenine and quinolinic acid, rather than just TRP degradation by itself [13,39,44,47,48,49].”
BackgroundMethodSelf-citationLicinio, J., & Wong, M.-L. (1999) · Molecular Psychiatry · doi:10.1038/sj.mp.4000586 · Cited by 380 · cited 1×
“increased production of positive acute phase proteins (APPs) and decreased production of negative APPs, are associated with depression [13,14,17,18,19,20,21].”
BackgroundMaes, M., Scharpé, S., Meltzer, H. Y., Okayli, G., Bosmans, E., D'Hondt, P., Vanden Bossche, B., & Cosyns, P. (1994) · Psychiatry Research · doi:10.1016/0165-1781(94)90003-5 · Cited by 302
PERSOONS, P., VERMEIRE, S., DEMYTTENAERE, K., FISCHLER, B., VANDENBERGHE, J., VAN OUDENHOVE, L., PIERIK, M., HLAVATY, T., VAN ASSCHE, G., NOMAN, M., et al. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02535.x · Cited by 253 · cited 3×
“There are numerous studies showing that depression exacerbates CD and predicts lower remission rates in CD [5,6,7,12].”
BackgroundMardini, H. E., Kip, K. E., & Wilson, J. W. (2004) · Digestive Diseases and Sciences · doi:10.1023/b:ddas.0000020509.23162.cc · Cited by 211 · cited 2×
“There are numerous studies showing that depression exacerbates CD and predicts lower remission rates in CD [5,6,7,12].”
BackgroundResultDo Life Events or Depression Exacerbate Inflammatory Bowel Disease?: A Prospective Study
North, C. S., Alpers, D. H., Helzer, J. E., Spitznagel, E. L., & Clouse, R. E. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-5-381 · Cited by 152
Mood and nonmood components of perceived stress and exacerbation of Crohnʼs disease
Cámara, R. J. A., Schoepfer, A. M., Pittet, V., Begré, S., & von Känel, R. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21623 · Cited by 67 · cited 2×
“There are numerous studies showing that depression exacerbates CD and predicts lower remission rates in CD [5,6,7,12].”
BackgroundResultKenis, G., Prickaerts, J., van Os, J., Koek, G. H., Robaeys, G., Steinbusch, H. W. M., & Wichers, M. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000830 · Cited by 58
Self-citation
Cited by
Increased Tryptophan Metabolism Is Associated With Activity of Inflammatory Bowel Diseases
Nikolaus, S., Schulte, B., Al-Massad, N., Thieme, F., Schulte, D. M., Bethge, J., Rehman, A., Tran, F., Aden, K., Häsler, R., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.08.028 · Cited by 602
Panara, A. J., Yarur, A. J., Rieders, B., Proksell, S., Deshpande, A. R., Abreu, M. T., & Sussman, D. A. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12669 · Cited by 168
“symptoms with anti-TNF treatments occurs independently of IBD activity as was recently shown among a small cohort of IBD patients.(24) Further prospective studies in the IBD population are needed.”
BackgroundBortolato, B., F. Carvalho, A., K. Soczynska, J., I. Perini, G., & S. McIntyre, R. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630171433 · Cited by 142
The Immune System and Electroconvulsive Therapy for Depression
Guloksuz, S., Rutten, B. P. F., Arts, B., van Os, J., & Kenis, G. (2014) · The Journal of ECT · doi:10.1097/yct.0000000000000127 · Cited by 90
Self-citationHorst, S., Chao, A., Rosen, M., Nohl, A., Duley, C., Wagnon, J. H., Beaulieu, D. B., Taylor, W., Gaines, L., & Schwartz, D. A. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3375-0 · Cited by 75
“A recent prospective study of fifteen patients with Crohn’s disease also suggested improvement in depressive symptoms within 8 weeks after treatment with one infusion of anti-TNF therapy, infliximab [19].”
Background
Metadata
- Authors
- Guloksuz, S., Wichers, M., Kenis, G., Russel, M. G. V. M., Wauters, A., Verkerk, R., Arts, B., & van Os, J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-03-27
- Volume
- 8
- Issue
- 3
- Pages
- e60435
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2062789759
- Cited by
- 52
- References
- 19
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.